Cybin Corp. and IntelGenx Corp. Enter Into Feasibility Agreement for Fast-Acting, Orally-Dissolving Psilocybin Film
Cybin Corp. (“Cybin” or the “Company”), Canada's premier mushroom life sciences company focused on advancing psychedelic and nutraceutical-based products derived from fungi, is pleased to announce that it has entered into a feasibility agreement with IntelGenx Corp. (OTCQB:IGXT; TSX-V:IGX) (“IntelGenx”) for the development of an orally-dissolving film for the delivery of pharmaceutical-grade psilocybin, subject to receipt of all necessary regulatory approvals.
“We at Cybin are proud to be working with IntelGenx to develop a fast-acting psilocybin film,” said Cybin’s Chief Medical Officer, Dr. Jukka Karjalainen. “Compared to oral psilocybin capsules, which are subject to variable intestinal absorption and high first-pass metabolism in the liver, the systemic bioavailability of orally-dissolving psilocybin film is expected to be quite high. In addition, the dose of psilocybin administered by an orally-dissolving film is expected to be a fraction of what is required in oral capsules. Taken together, these features have the potential to increase both the safety and efficacy of psilocybin when administered in this manner.”
“Cybin's intention with an orally-dissolving psilocybin film is to bypass the digestive system, which will provide faster-acting relief for individuals with anxiety disorders who require more immediate symptom relief,” added Cybin’s Chief Executive Officer, Paul Glavine.
Dr. Horst G. Zerbe, CEO of IntelGenx, commented, “This partnership exemplifies both the versatility and clinical advantages of our VersaFilm® technology platform. In addition to offering patients a convenient method of administration, our technology offers superior drug bioavailability, which decreases both the amount of active pharmaceutical ingredient required per dose, as well as time to onset of action, which are paramount when treating distressing conditions such as anxiety. We are looking forward to working with Cybin to realize these potential benefits for patients struggling with mental health disorders.”
About Cybin
Cybin is a mushroom life sciences company advancing psychedelic and nutraceutical-based products. The Company expects to launch psilocybin-based products in jurisdictions where the substance is not prohibited. Simultaneously, the Company is structuring and supporting clinical studies across North America and other regions, through strategic academic and institutional partnerships.
About IntelGenx
IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical delivery films.
IntelGenx’s superior film technologies, including VersaFilm® and VetaFilm™, as well as its transdermal development and manufacturing capabilities, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx’s innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions.
IntelGenx’s highly skilled team provides comprehensive pharmaceutical services to pharmaceutical partners, including research and development, analytical method development, clinical monitoring, intellectual property and regulatory services. IntelGenx's state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot-and commercial-scale production. For more information, visit www.intelgenx.com.
Forward Looking Statements
Certain statements in this press release constitute forward-looking information. All statements other than statements of historical fact contained in this press release, including, without limitation, those regarding the ability to receive regulatory approvals, the bioavailability of the film, the potential safety and efficacy of psilocybin administered in an orally-dissolving film, statements regarding Cybin’s future, strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words “believe”, “expect”, “aim”, “intend”, “plan”, “continue”, “will”, “may”, “would”, “anticipate”, “estimate”, “forecast”, “predict”, “project”, “seek”, “should” or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only Cybin’s expectations, estimates and projections regarding future events. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. The forward-looking information and forward-looking statements included in this press release are made as of the date of this press release. The Company does not undertake an obligation to update such forward-looking information or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities law.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200707005296/en/
Contact information
Sara Brittany Somerset
Email: sarabrittany@cybin.com
www.cybin.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Swiss Rockets Announces Strategic Exclusive License Acquisition of Cutting-Edge Sequencing Technology from MGI Tech and Complete Genomics28.10.2025 18:34:00 EET | Press release
Swiss Rockets, MGI US LLC and Complete Genomics Inc. announced today that they entered into a exclusive license agreement with MGI Tech and Complete Genomics, USA, granting Swiss Rockets a perpetual, transferrable, sublicensable, freedom-to-operate, license for USA, Europe, Latam, Africa and Central Asia with option to expand rights into Asia-Pacific in 2026, covering patents and other intellectual property necessary for development, manufacturing, and sales of the next-generation CoolMPS sequencing platform that will provide faster, cheaper and more accurate whole genome sequencing and other omics tests. The agreement includes payments linked to technology transfer and revenue-based royalties. Swiss Rockets’ future development will focus on advancing CoolMPS products with innovative read barcoding. These innovations will support comprehensive omics testing for advanced genomic research and molecular health monitoring. CoolMPS chemistry provides the most advanced MPS/NGS generating cos
Osmose Acquires Centillion Solutions, Inc. to Expand Its Technical Services Capabilities28.10.2025 16:00:00 EET | Press release
Osmose Utilities, Inc. today announced that it has acquired Centillion Solutions, Inc., a leading engineering services company for the telecommunications industry. Centillion provides fiber optic engineering, design, drafting and geospatial services for Fiber-to-the X (FTTx) and Hybrid Fiber Coax Networks. Founded in 2007, the company has offices in the U.S., Netherlands, UK, Australia, as well as a global design and engineering operation center in India. The acquisition of Centillion Solutions will further position Osmose with the ability to serve as a single vendor of technical services for telecom companies, providing comprehensive turn-key solutions that include pre-design walkout, Outside Plant (OSP) design, make-ready and permitting, and post construction services. “The addition of Centillion expands Osmose’s ability to deliver a complete, end-to-end fiber engineering solution providing customers with one trusted partner for planning, design, and delivery at scale,” said Mike Ada
Merck Partners with Promega to Advance 3-D Cell Drug Discovery Technologies28.10.2025 15:16:00 EET | Press release
Merck, a leading science and technology company, has entered into a partnership with Promega Corporation, a global life science solutions and service leader based in Madison, Wisconsin in the US, to co-develop novel technologies that advance drug screening and discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251028493228/en/ Merck and Promega will co-develop novel technologies that advance drug discovery. The agreement unites Merck’s strength in organoids and synthetic chemistry with Promega's market leading assay and reporter technologies. Together, the companies aim to develop assays capable of tracking cellular activity in real time using an innovative reporter system within three-dimensional (3D) cell cultures. These 3D cell cultures, also called organoids, mimic the human biology, where testing can be done in a model that is physiologically more relevant than traditional two-dimensional (2D) models. “This partn
Guidewire Signs Definitive Agreement to Acquire ProNavigator28.10.2025 15:00:00 EET | Press release
CONNECTIONS CONFERENCE--Guidewire (NYSE: GWRE) today announced that it has entered into a definitive agreement to acquire ProNav Technologies Ltd. (d/b/a ProNavigator), a knowledge management platform purpose-built for the P&C insurance industry. ProNavigator delivers precise, context-aware best practice information directly within insurance workflows, helping professionals work faster and more effectively. Its platform captures, connects, and surfaces institutional knowledge across claims, underwriting, and distribution. Used by 34 insurance organizations, including 12 shared customers with Guidewire, ProNavigator helps increase productivity, reduce claim cycle times, personalize customer service, and accelerate employee onboarding. Once the acquisition is complete, Guidewire will integrate ProNavigator’s insurance-trained intelligence across its platform, delivering advanced search and contextual knowledge retrieval capabilities for underwriters, claims adjusters, brokers, agents, an
Biometrics Named the Top Fraud-Fighting Tool, Regula Study Finds28.10.2025 15:00:00 EET | Press release
As deepfakes and other impersonation attacks already hit one in three businesses worldwide, companies are resetting their defenses around biometrics. A new survey by Regula, a global developer of identity verification (IDV) solutions and forensic devices, shows that while biometrics currently ranks third in adoption, it is seen as the #1 must-have tool in the ideal future stack. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251028919490/en/ Except for the telecom and banking sectors, which are already leveraging biometrics in full, other industries are aiming to increase their adoption of biometric verification tools. Based on the survey responses, biometrics stands out for both adoption and staying power, unlike other IDV methods: on a global level, it has the lowest drop-off rate among users and the highest growth potential, with 21% of non-users planning to add it soon. What’s happening now Today, most companies still re
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom